Navigation Links
Major Clinical Study Supports NIPT As First Line Screening Test For All Pregnant Women
Date:8/13/2014

SAN CARLOS, Calif., Aug. 13, 2014 /PRNewswire/ -- Natera, Inc., a leader in non-invasive genetic testing, today announced a study to be published in the November issue of American Journal of Obstetrics and Gynecology, which shows that Panorama™ NIPT performs consistently well in all pregnant women, regardless of their prior risk level. This is the largest ever published study of clinical outcomes with NIPT, following more than 17,000 consecutive cases originally analyzed by Natera in mid-2013. It is also the second in a series of published studies showing strong test performance in low risk populations.

"This study supports the use of NIPT as a first line screening test for aneuploidy," said lead author Peer Dar, MD, Head of Fetal Medicine at Montefiore Medical Center in New York. "These results are consistent with recent NIPT guidelines published by the American College of Medical Genetics and Genomics (ACMG) that do not distinguish between high risk and low risk pregnancies, and which recommend NIPT in conjunction with first trimester ultrasound."

Key findings of this study:

  • Performance of the Panorama NIPT, determined previously in published case-controlled validation studies, has now been confirmed in a clinical setting with this study, the largest clinical outcomes study of NIPT to date. 
  • NIPT is already being adopted by some low-risk women and their healthcare providers, with 49% of the cases in this clinical study from women under 35 years of age.
  • The authors find that there are no concerns about performance of NIPT as a first line screen, and it will be accessibility and affordability that determine universal adoption.
  • The study highlighted an important performance metric: positive predictive value (PPV). Panorama's demonstrated PPV is significantly higher than traditional serum screening, by an order of magnitude. This should translate to a significant reduction in unnecessary invasive procedures and enhanced patient safety.

The results of this study, entitled "Clinical experience and follow-up with large scale single-nucleotide polymorphism-based non-invasive prenatal aneuploidy testing," by lead author Dr. Peer Dar and senior author, Dr. Peter Benn, are available online at www.ajog.org.

About Natera

Natera is a genetic testing company that designs targeted assays to analyze tiny quantities of DNA. The mission of the company is to help families diagnose and manage genetic disease. In pursuit of that mission, Natera operates a CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, Calif., currently offering a host of preconception and prenatal genetic testing services primarily to OBGYN physicians and in-vitro fertilization centers. In 2013, the company launched Panorama™, a safe, simple test for pregnant women that screens for the most common chromosomal anomalies in a fetus as early as nine weeks of gestation. Tests developed by Natera have not been cleared or approved by the U.S. Food and Drug Administration (FDA). For more information, visit www.natera.com.

Contacts
GOLD PR for Natera
Shari Gold
714-251-0375
sgold@goldpr.com

Natera, Inc.
Mike Hromadik, 858-442-2215
mhromadik@natera.com


'/>"/>
SOURCE Natera, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Data from Study of Elderly Depressed Patients are Reported for Investigational Compound Lu AA21004 on Symptoms of Major Depressive Disorder (MDD)
2. Omega Laboratories Applauds the Adoption of Enzyme Immunoassay (EIA) by Major Hair Testing Laboratories
3. Tetra Discovery Partners Receives Major NIH Award To Develop New Alzheimers Drug
4. LIVE VIA SATELLITE: Physician Demonstrates New Medical Technology to Combat Back Pain without Major Surgery
5. First Patients Dosed in Ib Phase of Neuralstems NSI-189 Trial in Major Depressive Disorder
6. Cardiosolutions, Inc. Gathers Major Investment from Sorin Group
7. PTC Therapeutics Announces Achievement of Major Milestone in Wellcome Trust BMI1 Collaboration
8. Misonix Exhibits at Major Worldwide Spine Conference
9. Rheumatoid Arthritis New Major Clinical Target After Mesoblast Obtains Positive Results in Inflammatory Arthritis
10. Aribex Reaches Major Milestone, Builds 10,000th NOMAD Handheld X-ray
11. Major Breakthrough in Hepatitis C Vaccine Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 2017  Eli Lilly and Company (NYSE: ... $850 million in its U.S. operations in 2017. ... enterprise, including research laboratories, manufacturing sites, and general ... by demand for Lilly products, as well as ... targeting cancer, pain, diabetes and other unmet medical ...
(Date:3/24/2017)... , March 23, 2017  Mirabilis Medical, ... advanced medical technology for non-invasive surgery, announced today ... System for treatment of uterine fibroids throughout the ... had received approval from the US Food and ... the Mirabilis System in the United States.  The ...
(Date:3/24/2017)... , March 24, 2017 ... to develop sutezolid as effective response to infectious disease ... Alliance and the Medicines Patent Pool (MPP) announced a ... antibiotic drug candidate which demonstrated encouraging results in early ... in combination with other TB drugs and follows the ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... Mediaplanet today announces distribution ... the current obstacles facing infection prevention and offer strategies for the health care ... infections. , The print component of “Fighting Infection” is distributed within the ...
(Date:3/24/2017)... ... 24, 2017 , ... Texas Physical Therapy Specialists (TexPTS) is pleased to ... Road. The clinic is the group’s 7th location in San Antonio and 23rd in ... will provide care from the clinic, which opened March 22, 2017. , ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... (ONS) wanted to create a communications platform that positions them as the go-to ... and ONS reinvented their online publication as an always-on, always-fresh news, views and ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... announced their partnership to prep patients for colonoscopy at the HyGIeaCare® Center that ... 87th Ave., Miami, FL. , The HyGIeaCare® Prep, cleared by the ...
(Date:3/24/2017)... ... , ... “Vintage and Harvest A Cultivation of Christian Love” is the creation ... North Carolina with his wife, Anna Marie. He and his wife are the proud ... also the author of “Shadow and Substance.” , “Love, the agape kind, is seen ...
Breaking Medicine News(10 mins):